A series of GLP-1R agonists with resistance to dipeptidyl dipeptidase-IV breakdown are used routinely to treat type-2 diabetes (Table 1) and can be administered daily to weekly (Khoo & Tan 2020). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.